iPS Cells for Modelling and Treatment of Retinal Diseases.

Abstract

For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration.

• Authors: Fred K Chen, Samuel McLenachan, Michael Edel, Lyndon Da Cruz, Peter J Coffey, David A Mackey
• Journal: Journal of clinical medicine (J Clin Med) Vol. 3 Issue 4 Pg. 1511-41 (Dec 19 2014) ISSN: 2077-0383 [Print] Switzerland
• PMID: 26237613 (Publication Type: Journal Article, Review)